Skip to main content
Dennis Jingzhou Wang, MD, Gastroenterology, Loma Linda, CA

Dennis JingzhouWangMDMSc

Gastroenterology Loma Linda, CA

Gastroenterologist

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Wang's full profile

Already have an account?

  • Office

    11234 Anderson St
    B158
    Loma Linda, CA 92354

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Gastroenterology, 2021 - 2024
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 2018 - 2021
  • University of Virginia School of Medicine
    University of Virginia School of MedicineClass of 2018, MD
  • University of Toronto
    University of TorontoMS, Nutritional Science, 2012 - 2014
  • University of Toronto
    University of TorontoBS, Nutritional Science , 2008 - 2012

Awards, Honors, & Recognition

  • Poster of Distinction DDW, 2020
  • Oral Presentation DDW, 2019
  • Presidential Poster Award ACG, 2018

Publications & Presentations

PubMed

Journal Articles

  • Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction  
    Inessa Normatov, MD, Daniela Fluxa, MD, Jingzhou D Wang, MD, Jacob E Ollech, MD, George E Gulotta, MS, Shivani Patel, PharmD, Maria A Quintero, MPH, Bety De la To..., Crohn's and Colitis 360, 7/13/2021

Abstracts/Posters

  • RISK FACTORS AND TREATMENT OUTCOMES OF PERISTOMAL PYODERMA GANGRENOSUM IN INFLAMMATORY BOWEL DISEASE
    Jingzhou Wang, Joshua C. Prenner, Wenfei Wang, Atsushi Sakuraba, Neil Hyman, Sushila Dalal, Roger D. Hurst, Russell D. Cohen, Konstantin Umanskiy, Benjamin D. Shogan, ..., DDW, Chicago IL, 5/4/2020
  • Aseptic Meningitis With Multifocal White Matter T2 Hyperintensity In A Patient With Ulcerative Colitis On Vedolizumab: A Case Report
    Jingzhou Wang, Anthony Kanelidis, Joel Pekow, Shannon Martin, Advances in IBD, Orlando FL, 12/14/2019
  • META-ANALYSIS: THE RISK OF DEVELOPING NEW ONSET INFLAMMATORY BOWEL DISEASE WITH INTERLEUKIN-17 BLOCKADE THERAPY
    Dennis Jingzhou Wang, Akihiro Yamada, Yuga Komaki, Fukiko Komaki, Dejan Micic, Atsushi Sakuraba, DDW, San Diego, 5/21/2019
  • Join now to see all

Press Mentions

  • P2221 - Polypharmacy May Represent an Independent Risk Factor of Disease Flare in Patients with Ulcerative Colitis
    P2221 - Polypharmacy May Represent an Independent Risk Factor of Disease Flare in Patients with Ulcerative ColitisOctober 9th, 2018

Professional Memberships

Other Languages

  • Chinese (Mandarin), Chinese (Cantonese)